Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Significant Segment Expenses

Significant segment expenses, as provided to the CODM are as follows:

		Three Months Ended March 31,
		2026	2025
Sales	$	424,889	341,264
Cost of sales (excluding depreciation expense)		158,606	117,266
Research and development expense		438,800	959,162
Other research and development expense 1		870,601	2,009,310
Total research and development expense		1,309,401	2,968,472
Sales and marketing expense		1,315,755	908,567
General and administrative expense		1,782,390	1,722,713
Depreciation and amortization expense		82,270	84,853
Total operating expenses		4,489,816	5,684,605
Total other income (expense), net		5,069,633	(440,420	)
Income (loss) before income taxes		846,100	(5,901,027	)
Income tax benefit		—	(4,188	)
Net income (loss)	$	846,100	(5,896,839	)

¹ Other research and development expense include clinical affairs, regulatory, manufacturing and quality assurance expenses.